Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Bosco Paes, John R. Fullarton, Barry S. Rodgers-Gray & Xavier Carbonell-Estrany. (2021) Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants. Current Medical Research and Opinion 37:7, pages 1149-1153.
Read now
Read now
Ashleigh A. McGirr, Kevin L. Schwartz, Upton Allen, Melinda Solomon & Beate Sander. (2017) The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model. Human Vaccines & Immunotherapeutics 13:3, pages 599-606.
Read now
Read now
Haben Y Abraha, Krista L Lanctôt & Bosco Paes. (2015) Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Review of Respiratory Medicine 9:6, pages 779-799.
Read now
Read now
Leonard B. Weiner, Anthony S. Masaquel, Mark J. Polak & Parthiv J. Mahadevia. (2012) Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. Journal of Medical Economics 15:5, pages 997-1018.
Read now
Read now
Marcello Lanari, Michela Silvestri & Giovanni A. Rossi. (2010) Palivizumab prophylaxis in ‘late preterm’ newborns. The Journal of Maternal-Fetal & Neonatal Medicine 23:sup3, pages 53-55.
Read now
Read now
Bosco Paes, Mara Cole, Andrew Latchman & Janet Pinelli. (2009) Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Current Medical Research and Opinion 25:9, pages 2191-2196.
Read now
Read now
Articles from other publishers (31)
Marine Jourdain, Mehdi Benchaib, Dominique Ploin, Yves Gillet, Etienne Javouhey, Come Horvat, Mona Massoud, Marine Butin, Olivier Claris, Bruno Lina & Jean-Sebastien Casalegno. (2022) Identifying the Target Population for Primary Respiratory Syncytial Virus Two-Step Prevention in Infants: Normative Outcome of Hospitalisation Assessment for Newborns (NOHAN). Vaccines 10:5, pages 729.
Crossref
Crossref
Raluca Daniela Bogdan, Roxana Elena Bohiltea & Adrian Ioan Toma. (2022) Respiratory Follow Up of the Premature Neonates—Rationale and Practical Issues. Journal of Clinical Medicine 11:6, pages 1746.
Crossref
Crossref
Jesse Papenburg, Isabelle Defoy, Edith Massé, Georges Caouette & Marc H Lebel. (2021) Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study. Journal of the Pediatric Infectious Diseases Society 10:3, pages 237-244.
Crossref
Crossref
Tiffany FitzpatrickJ. Dayre McNallyThérèse A. StukelHong LuDavid FismanJeffrey C. KwongAstrid Guttmann. (2021) Family and Child Risk Factors for Early-Life RSV Illness. Pediatrics 147:4.
Crossref
Crossref
Tiffany Fitzpatrick, James Dayre McNally, Therese A Stukel, Jeffrey C Kwong, Andrew S Wilton, David Fisman & Astrid Guttmann. (2021) Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017. Archives of Disease in Childhood 106:2, pages 173-179.
Crossref
Crossref
M. Elhalik, K. El-Atawi, S.K. Dash, A. Faquih, A.D. Satyan, N. Gourshettiwar, A. Khan, S. Varughese, A. Ramesh & E. Khamis. (2019) Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study. Canadian Respiratory Journal 2019, pages 1-8.
Crossref
Crossref
B. Resch, E. Eber, D. Ehringer-Schetitska, U. Kiechl-Kohlendorfer, I. Michel‑Behnke, T. Popow-Kraupp, M. Redlberger-Fritz, M. Seidel, V. Strenger, M. Wald, A. Zacharasiewicz & A. Berger. (2019) Respiratory-Syncytial-Virus-Prophylaxe mit PalivizumabRespiratory Syncytial Virus Prophylaxis with Palivizumab. Pädiatrie & Pädologie 54:6, pages 270-276.
Crossref
Crossref
Michelle L Butt, LouAnn Elliott & Bosco A Paes. (2018) Respiratory syncytial virus hospitalization and incurred morbidities the season after prophylaxis. Paediatrics & Child Health 23:7, pages 441-446.
Crossref
Crossref
Maarten O. Blanken, Bosco Paes, Evan J. Anderson, Marcello Lanari, Margaret Sheridan-Pereira, Scot Buchan, John R. Fullarton, ElizaBeth Grubb, Gerard Notario, Barry S. Rodgers-Gray & Xavier Carbonell-Estrany. (2018) Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatric Pulmonology 53:5, pages 605-612.
Crossref
Crossref
B. Resch, V. S. Bramreiter, S. Kurath-Koller, T. Freidl & B. Urlesberger. (2017) Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis. European Journal of Clinical Microbiology & Infectious Diseases 36:6, pages 1057-1062.
Crossref
Crossref
Ian Mitchell, Isabelle Defoy & ElizaBeth Grubb. (2017) Burden of Respiratory Syncytial Virus Hospitalizations in Canada. Canadian Respiratory Journal 2017, pages 1-9.
Crossref
Crossref
Josep Figueras-Aloy, Paolo Manzoni, Bosco Paes, Eric A. F. Simões, Louis Bont, Paul A. Checchia, Brigitte Fauroux & Xavier Carbonell-Estrany. (2016) Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infectious Diseases and Therapy 5:4, pages 417-452.
Crossref
Crossref
Joan L Robinson & Nicole Le Saux. (2015) Prévenir les hospitalisations pour l’infection par le virus respiratoire syncytial. Paediatrics & Child Health 20:6, pages 327-333.
Crossref
Crossref
Joan L Robinson & Nicole Le Saux. (2015) Preventing hospitalizations for respiratory syncytial virus infection. Paediatrics & Child Health 20:6, pages 321-326.
Crossref
Crossref
Colleen Wegzyn, Lim Kai Toh, Gerard Notario, Sophie Biguenet, Kristina Unnebrink, Caroline Park, Doris Makari & Michael Norton. (2014) Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infectious Diseases and Therapy 3:2, pages 133-158.
Crossref
Crossref
Gang Luo, Flory L. Nkoy, Per H. Gesteland, Tiffany S. Glasgow & Bryan L. Stone. (2014) A systematic review of predictive modeling for bronchiolitis. International Journal of Medical Informatics 83:10, pages 691-714.
Crossref
Crossref
Louis Bont. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1825
1854
.
Bernhard Resch. (2014) Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis. The Open Microbiology Journal 8:1, pages 71-77.
Crossref
Crossref
Andrea T. Borchers, Christopher Chang, M. Eric Gershwin & Laurel J. Gershwin. (2013) Respiratory Syncytial Virus—A Comprehensive Review. Clinical Reviews in Allergy & Immunology 45:3, pages 331-379.
Crossref
Crossref
Amir Kugelman & Andrew A. Colin. (2013) Late Preterm Infants: Near Term But Still in a Critical Developmental Time Period. Pediatrics 132:4, pages 741-751.
Crossref
Crossref
Alberto Dall'Agnola, Elisa Girardi & Renzo Beghini. (2013) The guidelines for the prophylaxis of RSV: the need to upgrade. Early Human Development 89, pages S91-S93.
Crossref
Crossref
Maarten O. Blanken, Hendrik Koffijberg, Elisabeth E. Nibbelke, Maroeska M. Rovers & Louis Bont. (2013) Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study. PLoS ONE 8:3, pages e59161.
Crossref
Crossref
B. Paes, I. Mitchell, A. Li & K. L. Lanctôt. (2012) A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). European Journal of Clinical Microbiology & Infectious Diseases 31:10, pages 2703-2711.
Crossref
Crossref
Pooja Harijan & Elaine M. Boyle. (2012) Health outcomes in infancy and childhood of moderate and late preterm infants. Seminars in Fetal and Neonatal Medicine 17:3, pages 159-162.
Crossref
Crossref
Marianne Bracht, Debbie Basevitz, Marilyn Cranis, Rose Paulley & Bosco Paes. (2012) Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective. Neonatal Network 31:6, pages 369-386.
Crossref
Crossref
Marianne Bracht, Debbie Basevitz, Marilyn Cranis & Rose Paulley. (2012) Impact of Respiratory Syncytial Virus. Drugs in R&D 11:3, pages 215-226.
Crossref
Crossref
Michelle L. Butt, Amanda Symington, Marianne Janes, LouAnn Elliott, Susan Steele & Bosco A. Paes. (2010) The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study. European Journal of Pediatrics 170:7, pages 907-913.
Crossref
Crossref
Bernhard Resch & Bosco Paes. (2011) Are late preterm infants as susceptible to RSV infection as full term infants?. Early Human Development 87, pages S47-S49.
Crossref
Crossref
J. Figueras Aloy & X. Carbonell Estrany. (2010) Recomendaciones de uso de palivizumab para la prevención de la infección por virus respiratorio sincitial en prematuros de 32 1 a 35 0 semanas de gestación. Anales de Pediatría 73:2, pages 98.e1-98.e4.
Crossref
Crossref
Giovanni A. Rossi, Michela Silvestri & Marcello Lanari. (2010) Should the American Academy of Pediatrics Respiratory Syncytial Virus Guidelines Be Modified?. Pediatrics 125:4, pages e1021-e1021.
Crossref
Crossref
Lone G. Stensballe, John R. Fullarton, Xavier Carbonell-Estrany & Eric A. F. Simões. (2010) POPULATION BASED EXTERNAL VALIDATION OF A EUROPEAN PREDICTIVE MODEL FOR RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION OF PREMATURE INFANTS BORN 33 TO 35 WEEKS OF GESTATIONAL AGE. Pediatric Infectious Disease Journal 29:4, pages 374-376.
Crossref
Crossref